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Abstract
Background: The hepatitis B virus (HBV) is a major etiological factor of inflammation and damage to the liver
resulting in hepatocellular carcinoma. Transcription factors play important roles in the disordered gene expression
and liver injury caused by HBV. However, the molecular mechanisms behind this observation have not been
defined.
Results: In this study, we observed that circulating prostaglandin (PGE) 2 synthesis was increased in patients with
chronic hepatitis B infection, and detected elevated cyclooxygenase (COX)-2 expression in HBV- and HBx-
expressing liver cells. Likewise, the association of HBx with C/EBPb contributed to the induction of COX-2. The
COX-2 promoter was hypomethylated in HBV-positive cells, and specific demethylation of CpG dinucleotides within
each of the two NF-AT sites in the COX-2 promoter resulted in the increased binding affinity of NF-AT to the
cognate sites in the promoter, followed by increased COX-2 expression and PGE2 accumulation. The DNA
methylatransferase DNMT3B played a key role in the methylation of the COX-2 promoter, and its decreased
binding to the promoter was responsible for the regional demethylation of CpG sites, and for the increased
binding of transcription factors in HBV-positive cells.
Conclusion: Our results indicate that upregulation of COX-2 by HBV and HBx is mediated by both demethylation
events and recruitment of multiple transcription factors binding to the promoter.
Background
Human hepatitis B virus (HBV) is a non-cytopathic par-
tially double-stranded DNA virus that causes acute and
chronic liver disease. HBV infection affects approxi-
mately 350 million people in the world [1], and is
strongly associated with the development of liver cirrho-
sis and hepatocelluar carcinoma (HCC) [2]. Even though
multiple factors have been implicated in HBV-associated
pathogenesis and carcinogenesis, the exact molecular
mechanism underlying chronic HBV-induced liver can-
cer remains largely unknown [3].
Data from HBV-infected individuals and in vitro
experiments have shown that activation of the intrahe-
p a t i cc y t o k i n en e t w o r km a yp l a ya ni m p o r t a n tr o l ei n
pathogenesis of acute and chronic liver inflammation
and injury caused by HBV infection. Expression of
tumor necrosis factor-a [4,5], interleukin-6 [6], induci-
ble nitric oxide synthase [7,8] and cyclooxygenase-2
[8,9] are increased in response to HBV infection, or are
involved in HBV-associated HCC development.
Cyclooxygenase-2 (COX-2) is an inducible COX iso-
form required for the biosynthesis of prostaglandins,
such as PGE2, and is primarily involved in pathological
processes such as inflammation, fibrogenesis, and car-
cinogenesis [10]. Increases in COX-2 and PGE2 have
been reported in chronic hepatitis, liver cirrhosis, and
hepatocellular carcinoma [8,9]. COX-2 is induced at
the transcriptional level by a variety of stimuli
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[10,11]. Its promoter region contains a TATA box, an
E box, and binding sites for a number of transcription
f a c t o r ss u c ha sN F - B, NF-AT/AP1, NF-IL6/C/EBP,
and CREB [10-13].
It is well accepted that viral proteins stimulate COX-2
expression, such as latent membrane protein 1 of
Epstein-Barr virus (EBV) [14], Gp120 [15] and Tat of
human immunodeficiency virus (HIV) [16], and core
and NS5A of human hepatitis C virus (HCV) [17]. We
have previously demonstrated that NS3 of HCV [18]
and the spike and nucleocapsid proteins of SARS-
associated coronavirus (SARS-CoV) [19,20] induce
COX-2 expression in virus infected cells. Upregulation
of COX-2 was also observed in liver tissues chronically
infected with HBV [21]. Recent studies have shown that
HBx, a 17.5 kDa multifunctional transactivator encoded
by the HBV genome [22], is likely the most important
determinant of COX-2 induction in human cells
infected with HBV. Importantly, this of COX-2 expres-
sion may contribute to the pathogenesis of HBV [23].
DNA methylation and histone modifications repre-
sent the major epigenetic mechanisms implicated in
the regulation of gene transcription in mammals. DNA
methylation is a predominant mechanism employed to
inactivate relevant genes during tumorigenesis asso-
ciated with HCC. DNA methylation occurs at carbon 5
of cytosine, primarily in the context of the CpG dinu-
cleotide. Recent findings support the hypothesis that
hypomethylation of the DNA surrounding the proxi-
mal promoter region is a prerequisite for gene activa-
tion, whereas hypermethylation leads to gene silencing
[24]. Mechanistically, there are a number of ways in
which DNA methylation can repress transcription. For
example, many of the trans factors known to bind to
sequences containing CpG dinucleotides do not bind
when the CpG doublets are methylated [25]. Identifica-
tion of methylated regions in the COX-2 promoter
during HBV infection will aid in understanding the
mechanisms by which this gene is regulated.
To study the influence of HBV on the expression of
COX-2, we first examined the amount of PGE2 in the
peripheral blood serum of patients with chronic hepati-
tis B. We also analyzed the mechanism of COX-2
upregulation in HBV-positive cells as well as in HBx-
transfected cells. Our results showed that COX-2
expression was induced in both HBV-positive and
HBx-expressing cells, and that activation of the COX-2
promoter by HBx depended on C/EBP and CREB bind-
ing sites, in which C/EBPb played an important role.
HBx directly interacted with C/EBPb,a n de n h a n c e di t s
binding to the COX-2 promoter. DNA methylation ana-
lysis revealed that global hypomethylation of the COX-2
promoter and specific demethylation of the NF-AT
binding sites occurred in HBV-positive cells. Among the
three DNA methyltransferases (DNMTs) present in
mammalian cells, DNMT3B played a key role in COX-2
promoter methylation, and its decreased affinity for the
promoter was responsible for the specific regional
demethylation and the increased binding of transcription
factors. Together, this study shows that both aberrant
epigenetic modifications and transcription factors con-
tribute to the HBV-induced COX-2 expression.
Results
Elevated serum PGE2 in HBV patients
High level expression of circulating PGE2 was observed
in patients with chronic HBV infection. As shown in
T a b l e1t h es e r u ml e v e l so fP G E 2w e r es i g n i f i c a n t l y
higher in patients with chronic hepatitis B infection in
comparison with healthy control individuals (mean ±
SEM 1393.9 ± 834.5 vs. 161.6 ± 79.2 pg/mL P < 0.01),
suggesting that HBV infection resulted in upregulation
of COX-2.
HBV and HBx expression upregulates COX-2 expression
and COX-2 promoter activity
Simultaneous expression of HBx and COX-2 has been
observed in liver specimens from chronic HBV patients
[26]. To test if expression of HBV influences COX-2,
Table 1 Demographic and baseline characteristics, serum levels of PGE2 from HBV patients and healthy individuals
Characteristic Healthy individuals (N = 102) Patients (N = 107)
Age (years) 42.5 ± 12.7 45.4 ± 13.8
Gender (male/female) 83/19 89/18
Race or ethnic group-no. (%) Asian 102 (100) 107 (100)
HBeAg (+/-) 0/102 42/65
HBV genotype (b/c) NA 16/91
WBC (cells/μl) 3615 ± 860 7602 ± 7640
ALT (U/L) <30 156.9 ± 174.9
HBV DNA (copies/ml) <500 9.9E + 07 ± 4.7E + 08
PGE2 (pg/ml) 161.6 ± 79.2 1393.9 ± 834.5
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was compared with that in HepG2.2.15 cells, which con-
tain an integrated HBV genome. We analyzed COX-2
mRNA expression by quantitative RT-PCR, and detected
an increase in COX-2 mRNA in HepG2.2.15 cells as
compared to HepG2 cells, which do not express HBV
(Figure 1A). The amount of COX-2 protein was next
estimated by Western blot analysis, and endogenous
COX-2 protein was increased in HepG2.2.15 cells
(Figure 1A), suggesting that the presence of HBV regu-
lates COX-2 expression. To test if the upregulation of
COX-2 correlates with the expression of HBx, a reporter
plasmid in which the COX-2 promoter was cloned
upstream of the luciferase gene (pCOX-2-Luc) was
transfected with pHBV-1.2 or pHBV-1.2*7 and the con-
trol plasmid pRL-TK into HepG2 human hepatoma
cells, which support HBV replication. pHBV-1.2 con-
tains 1.2-fold length of the HBV genome and retains the
ability to produce mature HBV virions. pHBV-1.2*7 is
an HBV mutant that does not express HBx. Luciferase
activity was measured in each sample, and results
showed that wild-type HBV activated COX-2 promoter
whereas the HBV mutant failed to induce COX-2 pro-
moter activation (Figure 1B). Since expression of lucifer-
ase in these cells could only come from activity at the
COX-2 promoter in the reporter plasmid, it is likely
that COX-2 expression is regulated by HBx at the level
of transcription. We next transfected HepG2 cells with
pCOX-2-Luc and increasing concentrations of the
pCMV-HBx plasmid, and found that HBx stimulated
the COX-2 promoter in a dose-dependent manner
(Figure 1C). To further confirm the effects of HBx on
COX-2 expression, the pCMV-HBx plasmid was transi-
ently transfected into HepG2 cells. qRT-PCR and wes-
tern blot analysis showed elevated level of COX-2
mRNA and protein in HBx transfeted cells (Figure 1D).
COX-2 is a key enzyme involved in prostaglandin
synthesis, as it converts arachidonic acid to PGE2 and
other prostanoids involved in inflammation and tumor
development [10,27]. Elevated COX-2 activity in HBV
or HBx expressing cells was next monitored by mea-
suring the accumulation of secreted PGE2 in culture
supernatants from HepG2.2.15 cells, or from HepG2
cells transfected with pCMV-HBx. As shown in Figure
1E, the concentration of PGE2 was higher in HBV-
positive or HBx-expressing cells as opposed to control
cells. We next confirmed the specificity of COX-2 reg-
ulation for PGE2 secretion by treating the cells with
NS-398, a selective inhibitor of COX-2. We found that
treatment with NS-398 significantly reduced the
amount of secreted PGE2 as compared to untreated
cells, confirming the specific relationship between
HBV- and HBx-induced COX-2 expression and PGE2
secretion (Figure 1E).
To show the consistency of the above results with
clinical manifestations of hepatitis B, we performed
qRT-PCR analysis of peripheral blood mononuclear cells
(PBMC) from hepatitis B patients. Results showed ele-
vated levels of COX-2 mRNA in PBMC of these people
compared with healthy individuals (Figure 1F).
C/EBPb plays a role in HBx-induced COX-2 promoter
activation
C/EBP, NF-B, and CRE are important regulators of the
COX-2 promoter [10-13]. To identify the cis-regulatory
elements in the COX-2 promoter that are responsive to
HBx, mutant reporter plasmids were constructed in
which the binding site of these factors was altered in the
COX-2 promoter. These altered promoters were cloned
upstream of the luciferase gene, and were transfected
into HepG2 cells with pCMV-HBx. Deletion or muta-
tion of the NF-B binding sites had little effect on the
activation of the COX-2 promoter by HBx (Figure 2A
and 2B), which is consistent with prior studies [23].
A single mutation in the C/EBP, CRE, or double muta-
tion in both, nearly abolished the activation of the
COX-2 promoter by HBx (Figure 2B). These results
show that the C/EBP and CRE binding sites are required
for COX-2 promoter activation by HBx, suggesting that
HBx induces COX-2 expression in a C/EBP- and CRE-
dependent manner.
The C/EBP transcription factor family contains at least
six members (C/EBPa-C/EBPζ). C/EBPb is widely
involved in inflammation and regulates gene transcrip-
tion in response to a variety of stimuli [28,29]. We next
investigated the role of C/EBPb in the activation of
C O X - 2b yH B x .A tl e a s tt h r e ei s o f o r m so fC / E B P b,
LAP* (38 kDa), LAP (35 kDa), and LIP (20 kDa) are
constitutively expressed in a variety of cell types. LAP
and LAP* both contain a transactivation domain and a
DNA binding domain, whereas LIP only contains a
DNA binding domain [28-30]. HepG2 cells were
cotransfected with pCOX-2-Luc, pCMV-HBx, and
pCMV-LAP or pCMV-LIP. Luciferase activity in each
sample was measured after 24 hours, and the expression
of each cognate protein was confirmed by Western blot.
A synergistic effect between HBx and LAP on the COX-
2 promoter was observed (Figure 2C). As expected, LIP
inhibited HBx-induced COX-2 promoter activation (Fig-
ure 2D), likely due to the absence of a DNA-binding
domain. These data indicate that HBx and C/EBPb
cooperatively activate COX-2 transcription.
HBx directly interacts with C/EBPb and stimulates binding
of C/EBPb to the COX-2 promoter
As a transcription coactivator, HBx interacts with sev-
eral members of the basal transcriptional apparatus. We
next tested if HBx directly interacts with C/EBPb,a si t
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mRNA and protein were detected by qRT-PCR and western blot respectively. (B) COX-2 promoter activity was measured by transfecting HepG2
cells with pCOX-2-Luc and pHBV-1.2 or pHBV-1.2*7, an HBx-deficient HBV mutant. A Renilla luciferase reporter vector pRL-TK was used as internal
control. Luciferase activity in each sample was measured at 48 hours post-transfection. All data were normalized to the Renilla luciferase value,
and are expressed as mean ± SD, n = 3 (*P < 0.05). (C) HepG2 cells were cotransfected with different amounts of pCMV-HBx, and with pCOX-2-
Luc and pRL-TK. Relative luciferase activities were measured at 48 hours post-transfection. Results are presented as fold induction over values
obtained in cells not transfected with HBx, and as mean ± SD, n = 3. (D) HepG2 cells were transfected with pCMV-HBx. 48 hours after
transfection COX-2 mRNA and protein were determined by qRT-PCR and western blot respectively. (E) PGE2 levels were detected in HepG2.2.15
or HepG2 cells transfected with pCMV-HBx compared with mock transfected cells. Cells were treated with the COX-2 inhibitor NS-398 at 100 μM
for 24 hours where indicated. Results are presented as mean ± SD, n = 3 (*P < 0.05). (F) The PBMC lysates from healthy individuals (H1 to H4) or
HBV patients (P1 to P4) were used to extract total RNA, COX-2 mRNA was then detected by qRT-PCR.
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Page 4 of 16Figure 2 C/EBPb plays a role in HBx-induced COX-2 promoter activation. (A) HepG2 cells were transfected with luciferase reporter plasmids
containing the wild-type COX-2 promoter (-891/+9), or with plasmids containing deletion mutants of the COX-2 promoter, along with pCMV-
HBx and pRL-TK. Luciferase activites were measured in each sample after serum starvation for 24 hours, and were compared to those obtained
from control cells transfected with empty vector. All data were normalized to the Renilla luciferase value and are presented as mean ± SD, n =
3. (B) HepG2 cells were transfected with luciferase reporter plasmids containing the wild-type COX-2 promoter, or with those containing point
mutations in the NFB, C/EBP and CRE binding sties in the COX-2 promoter, along with pCMV-HBx and pRL-TK. Luciferase activities were
measured as described in (A) (*P < 0.05). (C) HepG2 cells were transfected with pCOX-2-Luc, pCMV-HBx, pCMV-LAP, and pRL-TK, and luciferase
activity was measured as described in (A) (*P < 0.05). (D) HepG2 cells were transfected with pCOX-2-Luc, pCMV-HBx, pCMV-LIP and pRL-TK, and
luciferase activity was measured as described in (A) (*P < 0.05).
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Page 5 of 16is a component of this apparatus. HepG2 cells were
transfected with plasmids encoding GFP-HBx or GFP
alone, and cell lysates were immunoprecipitated with
anti-GFP antibodies followed by Western blotting with
antibody specific for C/EBPb. Our results showed that
HBx co-immunoprecipitated with endogenous C/EBPb
(Figure 3A), confirming an interaction between HBx and
the basal transcriptional machinery.
To further confirm an interaction between HBx and
C/EBPb, we employed the mammalian two-hybrid assay
in HepG2 cells. We constructed a vector containing the
activation domain of VP16 fused with the N terminus of
LAP (pVP16-LAP), and a vector containing HBx fused
at its N terminus to the DNA-binding domain of Gal4
(pM-HBx). In this assay, if an interaction occurs
between HBx and LAP, the activation domain of VP16
will be brought into contact with its DNA binding
domain, thus inducing transcription of the luciferase
gene in the pG5-Luc reporter plasmid. HepG2 cells
were transfected with these plasmids, in addition to the
control plasmid pRL-TK, and our results showed that
luciferase expression in cells transfected with both pM-
HBx and pVP16-LAP was much higher than in control
cells (Figure 3B), confirming a direct interaction
between HBx and C/EBPb.
Prior studies have suggested that HBx may interact
with bZip factors through the bZip domain, which pro-
motes the binding to and activation of target promoters
[31]. We therefore used EMSA analyses to investigate
the possibility that C/EBP factors activated by HBx bind
DNA. Nuclear extracts were prepared from HepG2 and
HepG2.2.15 cells (Figure 3C), or from HepG2 cells
transfected with pCMV-HBx (Figure 3D), and were
incubated with a
32P-labeled probe representing the C/
EBP binding site from the COX-2 promoter. Binding of
nuclear factors to the probe was significantly increased
in HepG2.2.15 and in HBx-expressing cells (Figure 3C,
lanes 2 and 3, and Figure 3D, lanes 2 and 3). This inter-
action was eliminated when unlabeled probe was
included in the sample (Figure 3C and 3D, lane 4), but
was not affected by the addition of a C/EBP mutant
probe (Figure 3C and 3D, lane 5). Supershifted com-
plexes were observed when C/EBPb antibody was added
(Figure 3C, lane 6), confirming that HBx induces the
binding of C/EBPb to the COX-2 promoter.
We next confirmed the HBx-induced C/EBPb binding
to the COX-2 promoter using chromatin immunopreci-
pitation assays (ChIP). Chromatin fragments were pre-
pared from HepG2 cells transfected with pCMV-HBx,
and were immunoprecipitated with C/EBPb antibody.
The COX-2 promoter region, consisting of nucleotides
-155 to -2 relative to the transcription start site and
containing C/EBP binding sequences, was amplified
from the chromatin precipitates by PCR. We observed
that the amount of C/EBPb bound to the COX-2 pro-
moter was higher in the presence of HBx (Figure 3E,
lane 3) as opposed to cells not expressing HBx
(Figure 3E, lane 4). Taken together, these data suggest
that HBx stimulates the binding of C/EBPb to the COX-
2 promoter.
Demethylation activates COX-2 promoter activity in HBV-
positive cells
HBV infection and expression of HBx cause aberrant
methylation of tumor gene promoters [32], and the
demethylating agent 5-aza-CdR has been previously
used to investigate the role of methylation on gene
expression [33,34]. Here, HepG2 cells were transfected
with pCOX-2-Luc and pRL-TK, and 5-aza-CdR was
added to a final concentration of 1, 2, or 4 μMa f t e r6
hours. At 24 and 48 hours post-transfection, cells were
harvested for qRT-PCR, or Western blot and luciferase
assays, respectively. As shown in Figure 4A, the
addition of 5-aza-CdR stimulated both promoter
activity and the expression level of COX-2 in a dose-
dependent manner.
We next used bisulfate sequencing to obtain more
precise information concerning the methylation status
of the COX-2 promoter, as this method permits high
sensitivity mapping of methylated cytosine residues [35].
As shown in Figure 4B, the COX-2 promoter was
sequenced from genomic DNA isolated from HepG2
cells, from nucleotides -204 to +57, and was found to
contain 11 methylatable CpG sites. Bisulfite-modified
genomic DNA was then PCR amplified for the COX-2
promoter, and the products were cloned and sequenced.
The percentage of methylated CpGs was significantly
lower in HepG2.2.15 cells (35.7%) than in HepG2 cells
(59.1%) (Figure 4C). Importantly, two known NF-AT
motifs (-73 and -165), both of which contain a CpG site,
were demethylated on the COX-2 promoter in HBV-
expressing HepG2.2.15 cells, indicating that site-specific
demethylation of NF-AT sites are essential for NF-AT
binding and COX-2 promoter activation.
We next tested the influence of methylation on the
affinity of NF-AT to its binding motif on the COX-2
promoter. We performed EMSA using nuclear extracts
from HepG2.2.15 cells and a NF-AT probe spanning
nucleotides -85 to -66 of the COX-2 promoter. As
shown in Figure 4D, methylation of these nucleotides
inhibited the formation of DNA-protein complexes, sug-
gesting that the binding affinity between NF-AT and the
COX-2 promoter after demethylation of the CpG dinu-
cleotide on its binding motif was enhanced. Taken
together, these results suggest that hypomethylation of
the COX-2 promoter, especially at the NF-AT binding
sites, activates COX-2 promoter activity in HBV-expres-
sing cells.
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Page 6 of 16Figure 3 HBx directly interacts with C/EBPb and stimulates binding of C/EBPb to the COX-2 promoter. (A) HepG2 cells were transfected
with plasmids encoding GFP-HBx or GFP alone. Cellular extracts were prepared and co-immunoprecipitated with anti-GFP antibody, and proteins
were resolved by SDS-PAGE. Blots were incubated with the antibodies indicated in the figure, and were developed with chemiluminescence. (B)
HepG2 cells were transfected with pG5-Luc, pRL-TK, pVP16-LAP, pM-HBx, or empty vectors, as indicated. Luciferase activity was measured in each
sample, and was compared to those obtained from control cells. All data are normalized to the Renilla luciferase value, and are presented as
mean ± SD, n = 3 (*P < 0.05). (C) Nuclear extracts were prepared from HepG2.2.15 and HepG2 cells, and were mixed with a
32P-labeled C/EBP
probe and analyzed by electrophoretic mobility shift assay (EMSA). Excess non-labeled C/EBP probe (100-fold) was used as a competitor.
Polyclonal anti-C/EBPb was incubated with nuclear extracts prior to addition of the probes, as indicated. (D) Nuclear extracts were prepared from
HepG2 cells transfected with pCMV-HBx, and with mock transfected cells, and were mixed with a
32P-labeled C/EBP probe and analyzed by
EMSA. Excess non-labeled C/EBP probe (100-fold) was used as a competitor. (E) HepG2 cells were transfected for 48 hours with pCMV-HBx or
pCMV-Tag2A, and ChIP assays were performed using 2 μg of anti-C/EBPb. Normal rabbit IgG was used as control. Immunoprecipitated DNA or
control DNA was collected and amplified using specific primers for the C/EBP binding site in the COX-2 promoter (nucleotides -155 to -2).
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Page 7 of 16Figure 4 Demethylation activates COX-2 promoter activity in HBV-positive cells. (A) Cells were seeded at a density of 1 × 10
6 cells/10 cm
dish and transfected with pCOX-2-Luc and pRL-TK. 5-aza-CdR was added to a final concentration of 1, 2, or 4 μM at 6 hours post-transfection.
Cells were allowed to grow for another 24 hours for qRT-PCR, and 48 hours for luciferase assays and Western blots. Luciferase data were
normalized to that of the Renilla luciferase value, and are presented as mean ± SD, n = 3. (B) Genomic sequencing data of the COX-2 promoter
in HepG2 cells. Potential methylation sites are indicated with vertical lines. (C) Genomic DNA from HepG2 and HepG2.2.15 cells was treated with
sodium bisulfite and PCR amplified for the COX-2 promoter. Amplicons were cloned and sequenced, and each row of circles represents a single
sequenced clone. The solid circles indicate methylated cytosines, while the open circles indicate unmethylated cytosines. (D) Nuclear extracts
were prepared from HepG2.2.15 cells and were mixed with a
32P-labeled unmethylated NF-AT probe, or with an in vitro methylated NF-AT
probe, and analyzed by EMSA. Excess non-labeled NF-AT probe was used as a competitor. wt: wild-type; methyl: methylated.
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In mammalian cells, precise somatic DNA methylation
patterns are established during gametogenesis and early
embryogenesis by three known DNA methytransferases
(DNMT), specifically DNMT1, DNMT3A, DNMT3B
[36]. All of these DNMTs are overexpressed in cancers
[37]. To test if HBV initiates transcription by demethyla-
tion, we examined potential differences in DNMT activ-
ity in HepG2 and HepG2.2.1.5 cells (Figure 5A). We
found that the activity of total cellular DNMTs were
increased in HepG2.2.1.5 cells, but was decreased in the
nucleus, suggesting that HBV expression attenuates the
activity of nuclear DNMTs which are involved in gene
regulation directly.
To determine which DNMT is involved in activating
the COX-2 promoter, HepG2 cells were transfected
with pCOX-2-Luc alone or with siRNA specific for
DNMT1, DNMT3A, or DNMT3B. As shown in Figure
5B, COX-2 promoter activity was downregulated after
knock-down of DNMT3A, and was upregulated by
knock-down of DNMT3B. Co-transfection of DNMT
expression plasmids with pCOX-2-Luc revealed that
DNMT3B decreased COX-2 promoter activity in a
dose-dependent manner, whereas DNMT3A increased
in activity (Figure 5C). We next investigated the recruit-
ment of these three DNMTs to the COX-2 promoter by
ChIP assay. Chromatin fragments were prepared from
HepG2 and HepG2.2.15 cells and were immunoprecipi-
tated with antibodies specific for DNMT1, DNMT3A, or
DNMT3B. The COX-2 promoter was then amplified by
PCR, and we found that DNMT3B binding to the COX-
2 promoter was reduced in HBV-expressing HepG2.2.15
cells, whereas that of DNMT3A and DNMT1 was
increased (Figure 5D). Same results were shown in
pHBV-1.2 transfected HepG2 cells (Figure 5D). A prior
study has shown diminishede x p r e s s i o no fD N M T 3 B
and increased expression of DNMT1 and 3A in HBx-
expressing cells [38]. So the different DNA binding affi-
nities may due to different expressions of DNMTs.
These findings, combined with previous results that the
COX-2 promoter is demethylated in HBV-expressing
cells, suggest that DNMT3B but not DNMT1 or
DNMT3A plays a key role in COX-2 promoter methyla-
tion, and that the decreased activity of DNMT3B in the
nucleus is likely responsible for hypomethylation of the
COX-2 promoter.
Discussion
In this study, we observed significant increases in PEG2
synthesis in patients with chronic hepatitis B infection,
and also detected elevated COX-2 expression in HBV
and HBx-expressing liver cells. We demonstrated a pre-
viously unrecognized mechanism of COX-2 regulation,
where demethylation-linked recruitment of multiple
transcription factors to the COX-2 promoter activated
HBV-induced COX-2 expression. Demethylation of CpG
dinucleotides within the NF-AT binding sites in the
COX-2 promoter resulted in the increased binding affi-
nity of NF-AT to the cognate sites in the promoter, fol-
lowed by increased COX-2 expression and PGE2
accumulation. The association of HBx with C/EBPb also
contributed to the induction of COX-2. Likewise,
DNMT3B played a key role in the methylation of the
COX-2 promoter, as the reduced binding between
DNMT3B and the COX-2 promoter was responsible for
the regional demethylation of the CpG sites, and for the
increased binding of transcription factors in HBV-posi-
tive cells.
COX-2, the inducible isoform of COX, is highly
expressed in response to various pro-inflammatory sti-
muli and other cellular stresses [10,11], and previous
studies have shown increased levels of COX-2 in a vari-
ety of human cancers [27]. Importantly, overexpression
of COX-2 is closely linked to viral infection [14-17].
Chronic infection with HBV or HCV is the leading
cause of liver cancer [1-3], and elevated expression of
COX-2 has been described in different liver cirrhosis
animal models and liver tissue from cancer patients
with chronic HBV or HCV infections [8,9,17,21]. HBx is
a transcriptional activator that is required for viral infec-
tion and contributes to HBV-associated hepatocarcino-
genesis [39]. Accumulating evidence suggests that HBx
activates a large number of cellular genes related to
HBV-associated HCC, including the COX-2 gene
[22,40]. Coexpression of HBx and COX-2 was detected
in chronic liver diseases associated with HBV infection
[26], and HBx also promotes tumor cell invasion by
inducing membrane type 1 matrix metalloproteinase
and COX-2 [23]. However, the molecular details of
COX-2 activation during chronic HBV infection remain
to be defined.
It has been well established that NF-B, C/EBP, and
CREB are the primary transcription factors responsible
for the regulation of COX-2 expression [10-13]. In this
study we demonstrated that the C/EBP and CRE binding
sites, but not those of NF-B, were critical for HBx-
induced COX-2 promoter activation. It is possible that
NF-B might be involved in COX-2 expression, but that
it is not directly responsible for that induced by HBx.
We investigated the effect of HBx and the C/EBPb
isoform on COX-2 promoter activity, as C/EBPb is
widely involved in inflammation and cellular prolifera-
tion of a number of cell types, including hepatocytes,
and regulates gene transcription in response to a varity
of stimuli [28,29]. We found that the effects of different
isoforms of C/EBPb played diverse roles in this process.
LAP (transcription activator) and HBx had a synergistic
effect on COX-2 promoter activation, whereas LIP
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Page 9 of 16Figure 5 DNMT3B is responsible for the hypomethylation of COX-2 promoter. (A) DNMT activities of both total cellular and nuclear
extracts from HepG2 and HepG2.2.15 cells were measured using the Epiquik DNA Methyltransferase activity assay kit (*P < 0.05). (B) HepG2 cells
were transfected with pCOX-2-Luc, pRL-TK, siDNMT1, siDNMT3A or siDNMT3B. Luciferase activites were measured after serum starvation for
24 hours, and all data were normalized to the Renilla luciferase value, and are presented as mean ± SD, n = 3 (*P < 0.05). (C) HepG2 cells were
transfected with pCOX-2-Luc, pCDNA-DNMT1, pCDNA-DNMT3A or pCDNA-DNMT3B. Luciferase activites were measured as in (B). (D) HepG2 or
HepG2.2.15 cells and HepG2 cells transfected with pHBV-1.2 or control vector were used in ChIP assays using 2 μg anti-DNMT1, -DNMT3A, or
-DNMT3B. Immunoprecipitated DNA or control DNA was collected and amplified using specific primers for the COX-2 promoter (nucleotides
-177 to -56).
Yue et al. Virology Journal 2011, 8:118
http://www.virologyj.com/content/8/1/118
Page 10 of 16(transcription repressor) led to a decrease in HBx-
induced COX-2 expression. These data suggest that C/
EBPb, cooperatively with HBx, activates COX-2 tran-
scription through the transactivation domain of C/EBPb.
Likewise, bZip transcription factors, such as CREB and
C/EBP, were reported to interact with HBx and target a
variety of promoters [31,40,41]. We detected a direct
interaction between HBx and C/EBPb,w h i c hm a yc o n -
tribute to the reinforcement of C/EBPb binding to the
COX-2 promoter, and the subsequent upregulation of
COX-2 expression.
Others have confirmed a direct correlation between
the expression of a given gene and its methylation status
[42], and previous studies have proposed promoter
methylation as a mechanism to regulate COX-2 expres-
sion in tumors [43-45]. Likewise, other studies have
shown that DNA methylation of certain promoters is
associated with HBV infection [32]. Since many of the
trans factors known to bind to sequences containing
CpG dinucleotides do not bind when such regions are
methylated, we looked for relationships between tran-
scription factor binding and aberrant epigenetic modifi-
cations in the COX-2 promoter during HBV infection.
Bisulfite sequencing analysis of the CpG island in the
promoter (nucleotides -204 to +57) revealed the hypo-
methylation of the COX-2 promoter in HBV-expressing
cells. More importantly, demethylation of two NF-AT
motifs, which contained CpG sites, was detected in
these cells, and EMSA data indicated a higher affinity of
NF-AT for the demethylated motif of the COX-2 pro-
moter. As a previous report found that HBx activates
the COX-2 promoter in an NF-AT dependent manner
[23], our results describe a possible mechanism for the
role of NF-AT in this process. Considering the complex
interactions of HBx, C/EBPb and NF-AT, demethylation
of NF-AT sites might lead to the binding of different
trans factors. These results suggest a potential mechan-
ism for the C/EBPb- and NF-AT-dependent COX-2
activation by HBV and HBx.
DNMT1 is activated by the Ras-AP-1 signaling path-
way [46], Hypermethylation of tumor suppressor genes
a r em e d i a t e db yD N M T 3 Ao rD N M T 3 B ,a n dd i m i n -
ished expression of DNMT3B was detected in
HBx-expressing liver cell lines, resulting in genomic
hypomethylation [38]. We investigated the role of these
three DNMTs in the epigenetic modifications of the
COX-2 promoter. We found that DNMT3B but not
DNMT1 or DNMT3A was critical for methylation of
the COX-2 promoter, and ChIP assays showed that the
b i n d i n go fD N M T 3 Bt ot h eC O X - 2p r o m o t e rw a s
decreased in HBV-expressing cells. A recent study
demonstrated the interaction of HBx with DNMT3A
and unraveled a possible mechanism involved in HBx-
mediated epigenetic modifications and gene regulation
[47]. In our study, we investigated the role of three
DNMTs (DNMT1, DNMT3A, DNM3B) in the epige-
netic modifications of the COX-2 promoter through
overexpression and siRNA technology. Considering both
the binding of DNMT3B and the total DNMTs activities
in the nucleus of HBV-expressing cells were decreased,
our results indicate that DNMT3B but not DNMT1 or
DNMT3A plays a major role in COX-2 promoter
methylation. The increased binding of DNMT1 and
DNMT3A to COX-2 promoter in HBV-expressing cells
indicates the complex situation in HBV-mediated epige-
netic modifications and gene regulation. It is possible
that DNMT3A may play a minor role in controlling
COX-2 expression through another mechanism. Other
researches have showed the importance of mitochon-
drial pathway in HBx-induced COX-2 expression [48].
We are more concerned about the aberrant epigenetic
modifications induced by HBx and its role as a tran-
scriptional coactivator in HBV induced COX-2
expression.
Conclusions
All the data above are consistent with the finding
that the COX-2 promoter is hypomethylated in HBV-
expressing cells, and suggests a possible mechanism for
transcriptional activation of COX-2 by HBV (Figure 6).
In normal cells, the COX-2 promoter is hypermethy-
lated and transcription repressors, such as DNMT3B,
bind to the methylated CpG sites and repress its activity.
After HBV infection, the expression of the virus and
HBx trigger demethylation of the COX-2 promoter by
down-regulating DNMT3B, which is responsible for the
methylation of the promoter. Methylation relieves
repression of the promoter and transcription factors
such as NF-AT and C/EBPb are able to bind. Interac-
tions between HBx and C/EBPb, NF-AT enhance the
recruitment of the complex to the COX-2 promoter, the
transcription machinery is assembled, and the COX-2
gene is expressed. Such a mechanism provides deeper
insights into the molecular mechanism of HBV-induced
COX-2 expression.
Materials and methods
Clinical samples
Peripheral blood samples were obtained from 107
patients with chronic hepatitis B admitted in Beijing 302
Hospital (89 males and 18 females with mean age
45.4 ± 13.8 years). Matched for sex and age, 102 healthy
individuals (83 males and 19 females with mean age
42.5 ± 12.7 years) with no history of liver disease were
randomly selected as controls from the local blood
donation center. The collection of blood samples for
research was approved by the Institutional Review Board
of the College of Life Sciences, Wuhan University in
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Page 11 of 16accordance with guidelines for the protection of human
subjects. Written informed consent was obtained from
each participant.
Plasmids and reagents
A plasmid carrying 1.2-fold length of HBV genome
(pHBV-1.2; subtype ayw) and the same plasmid with a
stop codon for amino acid 7 of HBx (pHBV-1.2*7) were
obtained from Dr. Robert Schneider [49]. Construction
of the luciferase reporter vector (pGL3) containing a
COX-2 promoter region (nucleotides -891 to +9), its
truncated or site-specific mutants, Flag-tagged Human
C/EBPb LAP, and C/EBPb LIP were reported previously
[50]. The HBx gene was amplified by PCR from
HepG2.2.15 cells, which contain the HBV genome. The
HBx amplicon was cloned into pCMV-Tag2A using
EcoRI and XhoI and into eGFP-C1 using XhoI and XbaI.
HBx and C/EBPb-LAP were cloned into the mammalian
two-hybrid assay plasmids pM (GAL4 DNA-binding
domain) and/or pVP16 (VP16 activation domain)
(Promega) between the EcoRIa n dXbaIs i t e s .D N M T 1 ,
DNMT3A, and DNMT3B siRNA plasmids were con-
structed by ligating the corresponding pairs of oligonu-
cleotides to pSilencer™2.1-U6 neo (Ambion, Inc.,
Austin, TX, USA) based on the target sequences
described previously [51].
EGTA, DTT, 5-aza-CdR, NS-398, and antibody against
Flag were purchased from Sigma (St. Louis, MO). Anti-
body against COX-2 was from Cayman (Ann Arbor, MI,
USA). Antibodies specific for b-actin, C/EBPb, GFP, and
DNMT1 were purchased from Santa Cruz (Santa Cruz,
CA, USA). Antibodies against DNMT3A and DNMT3B
were purchased from Cell Signaling Technology (Bev-
erly, MA, USA).
Cell culture
The human hepatoma cell-line HepG2 was grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), 100 U/mL penicillin, and 100 μg/mL
Figure 6 COX-2 expression induced by demethylation-linked recruitment of multiple transcription factors during HBV infection. (A) In
normal cells, the promoter region of COX-2 is hypermethylated, and transcription repressors such as DNMT3B bind to the methylated CpG sites
and repress activity of the COX-2 promoter. (B) After HBV infection, the expression of viral proteins triggers demethylation of the COX-2
promoter by down-regulating DNMT3B. Transcriptional repression is relieved and interactions between HBx and C/EBPb, NF-AT, and CBP/p300
enhance the recruitment of the complex to the promoter, resulting in expression of the COX-2 gene.
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Page 12 of 16streptomycin sulfate at 37°C in 5% CO2.T h e
HepG2.2.15 cell-line was derived from HepG2 cells and
stably expresses HBV (ayw), and was maintained in
DMEM containing 400 μg/mL G418.
Transfection and luciferase reporter gene assays
Cells were plated at density of 4 × 10
5 cells per 24-
well or 6-well plate, depending on the experiment,
and were grown to 80% confluence prior to transfec-
tion. Cells were transfected using Lipofectamine 2000
(Invitrogen) for 24 hours, after which they were
serum-starved for an additional 24 hours prior to har-
vest. A Renilla luciferase reporter vector pRL-TK was
used as internal control. Luciferase activity was mea-
sured in each sample 48 hours after transfection using
the dual-luciferase reporter assay system (Promega),
and Renilla luciferase activities were determined as
internal controls for transfection efficiency. Assays
were performed in triplicate and expressed as mean ±
SD relative to the vector or mock control samples,
which were set at 100%.
Quantitative RT-PCR analysis
Quantitative RT-PCR analysis was performed to deter-
mine relative mRNA levels. Total RNA was isolated
using TRIzol (Invitrogen). Cellular RNA samples were
reverse-transcribed using random primers. Real-time
PCR was performed in LightCycler 480 (Roche).
GAPDH was amplified as an internal control. The pri-
mers used were COX-2 up: 5’-TACAATGCTGAC-
TATGGCTAC-3’ and COX-2 down: 5’-ACTGATGC
GTGAAGTGCTG-3’;G A P D Hu p :5 ’-AAGGCTGT
GGGCAAGG-3’ and GAPDH down: 5’-TGGAG
GAGTGGGTGTCG-3’.
Western blot analysis
Whole-cell lysates were prepared by lysing cells with
PBS pH 7.4 containing 0.01% Triton X-100, 0.01%
EDTA, and 10% protease inhibitor cocktail (Roche). Pro-
tein concentration in each sample was determined using
the Bradford assay kit (Bio-Rad). One hundred micro-
grams of each sample was subjected to 12% SDS-PAGE,
followed by transfer to nitrocellulose membranes. Blots
were blocked with nonfat dried milk prior to incubation
with antibodies as indicated in the figures. Blots were
developed using SuperSignal Chemiluminescent reagent
(Pierce, Rockford, IL, USA) and quantified by densito-
metric analysis to show fold induction.
Quantification of prostaglandin E2
Cells were transfected as indicated in the figures for
24 hours, and were cultured for an additional 24 hours
in DMEM without FBS or antibiotics, and either with or
without NS-398 (100 μM). Conditioned media or blood
samples were used to quantify PGE2 using the PGE2
EIA kit according to the manufacturer’sp r o t o c o l( R & D
systems).
Immunoprecipitation
Cells were cultured in 10-cm dishes and were lysed in
800 μL lysis buffer (150 mM NaCl, 50 mM Tris/HCl
(pH 7.4), 0.5% (v/v) Nonidet P-40, and protease inhibi-
tor cocktail). Lysates were centrifuged at 14,000 ×g for
10 min, and 700 μL of each supernatant was incubated
with 30 μL of protein A/G sepharose for 30 min. Anti-
bodies (2 μg) were initially incubated with 50 μLo f5 0 %
(v/v) protein A/G-sepharose for 2 hours prior to addi-
tion to the lysate samples. Samples were incubated over-
night, and the beads were extensively washed. Bound
proteins were eluted from the beads and were resolved
by SDS-PAGE.
Mammalian two-hybrid assays
HepG2 cells were cultivated and transfected for
24 hours with 0.5 μg of pM and pVP16, 0.5 μg of repor-
ter pG5-Luc, and 0.01 μg of control pRL-TK (Promega).
Luciferase activity in each sample was determined using
the dual-luciferase reporter assay system.
Bisulfite modification and sequencing analysis
At o t a lo f2μg of genomic DNA was obtained from
HepG2 and HepG2.2.1.5 cells, and was modified by
sodium bisulfite. Primary and secondary PCR reactions
were carried out in 50 μL reaction mixtures. Primers
used to generate the primary PCR product were: COX-
2-nest up 5’-GGAGGGATTAGATAGGAGAG-3’ and
COX-2-nest down 5’-AAATAAACTTTACTATCTAA-
3’. To obtain products for sequencing, a secondary
round of PCR was performed using the primary PCR
products and the primers COX-2-up 5’-TTTAAAT
TGGGGTAGTTTTT-3’ and COX-2-down 5’-CTAC
TAAAAAATTCCTAAA-3’. Secondary PCR products
were gel-purified and cloned into a TA cloning vector
(Promega). Individual plasmids were verified by DNA
sequencing.
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared from HepG2 and
HepG2.2.15 cells according to methods described pre-
viously [20]. C/EBP and NF-AT oligonucleotides were
synthesized based on the human COX-2 promoter
sequence:
Wild-type C/EBP: 5’-GCTTACGCAATTTTTT-
TAAGG-3’;
Mutant C/EBP: 5’-GCGACTAGAATTTTTTTAAGG-3’;
NF-AT: 5’-ACGAAAAGGCGGAAAGAAAC-3’;
and Methyl NF-AT: 5’-ACGAAAAGGCGGAAA
GAAAC-3’.
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purified. Each probe was end-labeled with [g
32P]-ATP
using T4 polynucleotide kinase (Takara Biotech). EMSA
was performed by incubating 2 μg of nuclear extract with
labeled probes (15,000 cpm; 10 fmol) in binding buffer
(4 mM Tris-HCl, 12 mM HEPES-KOH, pH 7.9, 60 mM
KCl, 12% glycerol, 0.5 mM EDTA, and 1 mM DTT) con-
taining 1 μg of poly (dI-dC) for 25 min at room tempera-
ture. To ensure specific binding of transcription factors to
the probes, the probes were chased by 100-fold molar
excess of cold wild-type, mutant, or methylated oligonu-
cleotides. Samples were electrophoresed on 5% nondena-
turing polyacrylamide gels with running buffer (22.5 mM
Tris borate and 0.5 mM EDTA), and the gels were dried
and subjected to autoradiography.
Chromatin immunoprecipitation (ChIP)
HepG2 and HepG2.2.1.5 cells were incubated for 24 hours
after transfection (if transfection was necessary), after
which they were serum-starved for an additional 24 hours.
One percent formaldehyde was added to the culture med-
ium, and the cells were washed twice with PBS, scraped,
and lysed in buffer containing 1% SDS, 10 mM Tris-HCl
pH 8.0, and protease inhibitor cocktail, for 10 min on ice.
The lysates were sonicated on ice and the debris was
removed by centrifugation at 12,000 ×g for 15 min at 4°C.
One-fourth of the supernatant was used as DNA input
control. The remaining sample was diluted 10-fold with
dilution buffer (0.01% SDS, 1% Triton X-100, 1 mM
EDTA, 10 mM Tris-HCl pH 8.0, and 150 mM NaCl) fol-
lowed by incubation with antibodies against C/EBPb,
DNMT1, DNMT3A, or DNMT3B overnight at 4°C.
Immunoprecipitated complexes were collected using pro-
tein A/G-sepharose. The pellets were washed for four
times with dialysis buffer containing 2 mM EDTA and 50
mM Tris-HCl pH 8.0. After washing, the precipitates were
incubated in an elution buffer (1% SDS and 0.1 M
NaHCO3) at room temperature. Supernatants were trans-
ferred to clean tubes, and RNase A was added to destroy
bound RNA in the sample. Samples were incubated at 65°
C for 5 hours to reverse formaldehyde crosslinks, and
DNA was precipitated with ethanol and extracted two
times with phenol/chloroform. Pellets were suspended in
TE buffer and subjected to PCR amplification using the
COX-2 promoter detection primers C/EBP up: -155
TAAAAAA CCCTGCCCCCACCGG -134, C/EBP down:
-2 TCG CTAACCGAGA GAACCTTCCTT -25, DNM
Ts-b up: -177 CCGATTT TCTCATTTCCGTGGG -156,
and DNMTs-b down: -56 CGAAATGACTGTTTC
TTTCCGCC -78.
DNMT activity assays
Nuclear extracts and total cellular proteins from HepG2
and HepG2.2.1.5 cells were prepared and protein
concentrations were determined using the Bradford
assay kit (Bio-Rad). Equal amounts of protein were used
for DNMT activity measurement using the Epiquik
DNA methyltransferase activity assay kit according to
the manufacturer’s protocol (Epigentek Group).
Statistical analysis
All of the experiments were reproducible and were car-
ried out in duplicates or quadruplicates. Each set of
experiments was repeated at least three times with simi-
lar results. The results are presented at the means ±
S.D. Student’s t-test for paired samples was used to
determine statistical significance. Differences were con-
sidered statistically significant at a value of P ≤ 0.05.
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